Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call: Revenue Up 99%, Guidance Raised
Source Tradingkey
Key Takeaways
- Q2 2026 revenue increased 99% year over year to a record $37.6 million, led by the Hemangiol relaunch and growth across Increlex, the adrenal franchise, Galzin and carglumic acid.
- Adjusted EBITDA rose to $16.2 million, or 43% of revenue, from $3.1 million, or 16% of revenue, in Q2 2025. GAAP net income reached $11.6 million, or $0.35 per diluted share.
- Management raised full-year 2026 revenue guidance to more than $145 million from more than $120 million. Expected adjusted EBITDA margin increased to above 35% from above 30%.
- Hemangiol became Eton’s largest product following its May 1 relaunch. Approximately 95% of patients had transitioned to Eton Cares by the end of June, and management said the transition is now complete.
- Eton licensed ASN001, a late-stage topical treatment candidate for infantile hemangiomas. The company plans a 24-patient bioavailability study and expects to submit an NDA in the second half of 2027, potentially supporting a 2028 launch.
- Eton ended the quarter with $26.8 million in cash after a $3 million debt prepayment. The company plans to prioritize accretive product acquisitions while accelerating repayment of its remaining credit facility over the next six to 12 months.
Key Financial Data
| Metric | Q2 2026 | Q2 2025 | Change / Commentary |
|---|---|---|---|
| Revenue | $37.6 million | $18.9 million | Up 99% year over year |
| Gross profit | $25.4 million | $11.9 million | Up 113% |
| Adjusted gross profit | $27.4 million | $14.1 million | Adjusted margin was 73% versus 75% |
| R&D expense | $1.0 million | $3.7 million | Prior-year period included a Desmoda FDA filing fee |
| G&A expense | $11.6 million | $9.7 million | Up 20% |
| Adjusted EBITDA | $16.2 million | $3.1 million | Margin expanded to 43% from 16% |
| GAAP net income | $11.6 million | $(2.6) million | Diluted EPS of $0.35 versus a loss of $0.10 |
| Non-GAAP net income | $14.3 million | $1.5 million | Diluted EPS of $0.43 versus $0.03 |
| Cash at quarter-end | $26.8 million | — | After a $3 million debt prepayment |
Business and Operating Performance
Hemangiol and pediatric dermatology
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Financial Markets 2026: Volatility Catalysts in Gold, Silver, Oil, and Blue-Chip Stocks—A CFD Trader's OutlookGet a comprehensive financial market 2026 outlook exploring key economic drivers, volatility catalysts in gold, oil and stocks, and what the evolving economic outlook means for cfd trading strategies and risk management on global markets.
Get a comprehensive financial market 2026 outlook exploring key economic drivers, volatility catalysts in gold, oil and stocks, and what the evolving economic outlook means for cfd trading strategies and risk management on global markets.
As of the European session on August 11, gold prices (XAUUSD) briefly topped $4,400 intraday, reaching a high of $4,435.2, its highest level since June 5. However, gains subsequently narr
WTI declines below $82.50 as oil inventories rise far more than expectedWest Texas Intermediate (WTI), the US crude oil benchmark, is trading around $82.45 during the early Asian trading hours on Thursday. WTI declines on a larger-than-expected build in US crude oil inventories. Traders will closely monitor the developments surrounding US-Iran talks for fresh impetus.
West Texas Intermediate (WTI), the US crude oil benchmark, is trading around $82.45 during the early Asian trading hours on Thursday. WTI declines on a larger-than-expected build in US crude oil inventories. Traders will closely monitor the developments surrounding US-Iran talks for fresh impetus.
Here is what you need to know on Thursday, August 13:
WTI remains below $80.50 as traders monitor diplomatic efforts to reopen HormuzWest Texas Intermediate (WTI) oil price remains subdued for the third successive day, trading around $80.30 per barrel during the Asian hours on Friday. Crude oil prices edge lower as investors adopt a wait-and-see approach, closely monitoring diplomatic attempts to reopen the Strait of Hormuz.
West Texas Intermediate (WTI) oil price remains subdued for the third successive day, trading around $80.30 per barrel during the Asian hours on Friday. Crude oil prices edge lower as investors adopt a wait-and-see approach, closely monitoring diplomatic attempts to reopen the Strait of Hormuz.
